KR20240135692A - 질환의 성별-특이적 치료를 위한 nap - Google Patents

질환의 성별-특이적 치료를 위한 nap Download PDF

Info

Publication number
KR20240135692A
KR20240135692A KR1020247022758A KR20247022758A KR20240135692A KR 20240135692 A KR20240135692 A KR 20240135692A KR 1020247022758 A KR1020247022758 A KR 1020247022758A KR 20247022758 A KR20247022758 A KR 20247022758A KR 20240135692 A KR20240135692 A KR 20240135692A
Authority
KR
South Korea
Prior art keywords
day
pharmaceutical composition
subject
disease
nap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022758A
Other languages
English (en)
Korean (ko)
Inventor
일라나 고제스
가이 샤피라
알렉산드라 로빈체바
기돈 카르몬
노암 숌론
Original Assignee
라모트 앳 텔-아비브 유니버시티 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라모트 앳 텔-아비브 유니버시티 리미티드 filed Critical 라모트 앳 텔-아비브 유니버시티 리미티드
Publication of KR20240135692A publication Critical patent/KR20240135692A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247022758A 2021-12-14 2022-12-13 질환의 성별-특이적 치료를 위한 nap Pending KR20240135692A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163289174P 2021-12-14 2021-12-14
US63/289,174 2021-12-14
US202263306146P 2022-02-03 2022-02-03
US63/306,146 2022-02-03
PCT/IL2022/051314 WO2023112025A1 (en) 2021-12-14 2022-12-13 Nap for sex-specific treatment of diseases

Publications (1)

Publication Number Publication Date
KR20240135692A true KR20240135692A (ko) 2024-09-11

Family

ID=86773996

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022758A Pending KR20240135692A (ko) 2021-12-14 2022-12-13 질환의 성별-특이적 치료를 위한 nap

Country Status (9)

Country Link
US (1) US20250312408A1 (https=)
EP (1) EP4447994A4 (https=)
JP (1) JP2025501458A (https=)
KR (1) KR20240135692A (https=)
AU (1) AU2022410066A1 (https=)
CA (1) CA3240138A1 (https=)
IL (1) IL313226A (https=)
MX (1) MX2024006777A (https=)
WO (1) WO2023112025A1 (https=)

Also Published As

Publication number Publication date
EP4447994A1 (en) 2024-10-23
IL313226A (en) 2024-07-01
CA3240138A1 (en) 2023-06-22
WO2023112025A1 (en) 2023-06-22
AU2022410066A1 (en) 2024-07-25
MX2024006777A (es) 2024-08-06
JP2025501458A (ja) 2025-01-22
US20250312408A1 (en) 2025-10-09
EP4447994A4 (en) 2026-01-07

Similar Documents

Publication Publication Date Title
Dejanovic et al. Targeting synapse function and loss for treatment of neurodegenerative diseases
Pallotta et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
Busciglio et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome
Curcio-Morelli et al. Macroautophagy is defective in mucolipin-1-deficient mouse neurons
Guo et al. Alzheimer's disease and retinal neurodegeneration
Vilchez et al. The role of protein clearance mechanisms in organismal ageing and age-related diseases
Caldeira et al. Microglia change from a reactive to an age-like phenotype with the time in culture
Tseng et al. The deacetylase HDAC6 mediates endogenous neuritic tau pathology
Menéndez Down syndrome, Alzheimer's disease and seizures
Jaliffa et al. Sirt1 involvement in rd10 mouse retinal degeneration
Wang et al. Traumatic brain injury causes frontotemporal dementia and TDP-43 proteolysis
Wang et al. Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome
Chu et al. Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer’s disease
Alobuia et al. Axon degeneration is key component of neuronal death in amyloid-β toxicity
Babri et al. Effect of aggregated β-amyloid (1-42) on synaptic plasticity of hippocampal dentate gyrus granule cells in vivo
Singulani et al. Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
Olsson et al. Imatinib treatment and Aβ42 in humans
Park et al. Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product
KR102630042B1 (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
Straten et al. Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease
Liu et al. Effect of ginkgolide K on calcium channel activity in Alzheimer's disease
Xiao Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Panidis et al. The role of estrogen replacement therapy in Alzheimer’s disease
US20250312408A1 (en) Nap for sex-specific treatment of diseases
Lelos Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000